Clinical trial Recruiting at 1 site Observational Ages 18 and up

JAK1 and JAK2 activation in healthy versus inflamed gums

Official title: Unraveling the Role of JAK1 and JAK2 Pathway in Periodontitis: Drivers of Immunopathology and Possible Therapeutic Targets

Run by University of Chile · NCT07536204 · Data updated 2026-11-12

We will test whether the JAK1 and JAK2 immune-signaling pathways are more active in adults with periodontitis than in adults with healthy gums.

More Periodontitis trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorUniversity of Chile
Academic / other
Drugs / interventionsChemotherapy, radiation
Locations1 site (Santiago, Metropolitan Region)
StatusRecruiting
StartedJune 1, 2023
Main results expectedMarch 31, 2027
Study endsMarch 31, 2027
Registry record updatedApril 17, 2026
Trial IDNCT07536204 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults who are systemically healthy and able to undergo a single gingival biopsy visit, including those with clinically healthy gingiva or with periodontitis, who are not pregnant and do not have recent immunosuppressive or antibiotic exposure, are ideal candidates.

Probably not a fit

People with active malignancy, recent chemotherapy or head/neck radiation, chronic viral infections (HBV/HCV/HIV), autoimmune disease, diabetes, recent immunosuppressive or cytokine therapy, heavy smoking (>10 cigarettes/day), pregnancy or lactation are excluded and unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects gingival biopsy samples from adults with healthy gums and from adults with periodontitis at a single clinic visit. Tissue samples will be analyzed for JAK1 and JAK2 pathway activation and mapped to histological compartments such as epithelium and lamina propria and to specific cell subpopulations. All participants will receive diagnosis and standard dental treatment for their gingival condition. No experimental drug or device is administered.

Why it matters

Potential benefit: If successful, the findings could point to JAK1/2 as a target for new treatments that reduce gum inflammation and attachment loss.

How similar studies have gone: JAK pathway activation and JAK inhibitor benefit have been demonstrated in other inflammatory diseases, but applying detailed gingival biopsy profiling to link JAK1/2 specifically to periodontitis is a relatively novel, mechanistic approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults
* Sistemically healthy

Exclusion Criteria:

* Active Maliganancy
* History of radiation to the head-neck region
* Chemotherapy or radiation within the last 5 years
* History of hepatitis B/C or HIV infection
* Autoimmune diseases
* Diagnosis of diabetes
* Pregnancy or lactation
* More than 3 hospitalizations over the last 3 years
* Use of systemic antibiotics over the last 3 months
* Use of systemic corticosteroids or immunosuppressants over the last 3 months
* Use of cytokine therapy over the last 3 months
* Use of large doses of pre/probiotic supplements over the last 3 months
* Smoke more than 10 cigarettes per day

Where it's running

  • Faculty of Dentistry, University of Chile
    Santiago, Metropolitan Region, Chile
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.